Concordia inks deal with Japan's Ono; Elan shareholder to propose new board members;

 @FierceBiotech: Nobel Prize-winner finds new path for Alzheimer's drug. Story | Follow @FierceBiotech

 @JohnCFierce: Forbion Capital raised €190 million for a new fund. Good news for European biotechs. | Follow @JohnCFierce

> Concordia Pharmaceuticals has signed a licensing agreement with Japan's Ono Pharmaceutical for salirasib, a treatment for pancreatic, non-small cell lung and colorectal cancers. The agreement grants Ono the exclusive rights to develop and commercialize salirasib in Japan. Concordia release

> Next week, dissident shareholder Ib Sonderby plans to hold a conference call to introduce four proposed board members he would like to install at Elan. Report

> Gilead Sciences has sumited a marketing authorization application to the EMA for approval for the fixed-dose combination of Truvada for HIV-1 infection in adults. Gilead release

> Over the previous decade, the proportion of Americans (of all ages) reporting they took a prescription drug in the past month rose to 48 percent from 44 percent. Report

And Finally... Can cranberry juice prevent staph infections? Story